TrialArchives of osteoporosis2019

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.

Akimitsu Miyauchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.